Associations of body composition with neoadjuvant chemotherapy response, toxicity, and prognosis in breast cancer: a scoping review
Authors:
Open Access
- 12 August 2026
- journal article
- review article
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 96 (1) , 89
Abstract
Background: Breast cancer is the leading cause of cancer-related death in women worldwide. There is increasing interest in using detailed body composition parameters, such as skeletal muscle mass and adiposity, to better predict treatment response, toxicity, and survival in breast cancer patients receiving neoadjuvant chemotherapy (NAC). This study synthesised current literature on the effect of body composition in breast cancer patients undergoing NAC and identified gaps for future research. Methods: A scoping review was conducted in accordance with PRISMA-ScR and Arksey & O’Malley frameworks. Embase, MEDLINE, PubMed, and Google Scholar were searched for studies published between 2010 and 2025 to map available evidence. Eligible studies included female breast cancer patients receiving NAC with body composition assessment and at least one outcome of response, toxicity, or prognosis. Results: Twenty studies met inclusion criteria. Computed tomography at the L3 vertebral level was the most common assessment method. Findings were heterogeneous; 3 studies reported a statistically significant association between sarcopenia and reduced pathological response, while results for adiposity were inconsistent. Half of the studies assessing toxicity reported higher toxicity rates in patients with sarcopenia and/or adiposity. Prognostic findings were variable, with some studies reporting associations with visceral adiposity, and only one study reporting a significant association with sarcopenia. Conclusions: Evidence regarding the relationship between adiposity and NAC toxicity and prognosis in breast cancer remains suggestive, while findings for sarcopenia are inconsistent. Prospective, standardised studies are needed to clarify the role of body composition in breast cancer outcomes and its relevance in treatment planning.Keywords
Funding Information
- University of Sydney
This publication has 43 references indexed in Scilit:
- Call for standardization in assessment and reporting of muscle and adipose change using computed tomography analysis in oncology: A scoping reviewJournal of Cachexia, Sarcopenia and Muscle, 2023
- Hematologic toxicities, sarcopenia, and body composition change in breast cancer patients undergoing neoadjuvant chemotherapySupportive Care in Cancer, 2023
- Body composition and breast cancer risk and treatment: mechanisms and impactBreast Cancer Research and Treatment, 2021
- The association of body composition parameters and adverse events in women receiving chemotherapy for early breast cancerBreast Cancer Research and Treatment, 2020
- Muscle composition and outcomes in patients with breast cancer: meta-analysis and systematic reviewBreast Cancer Research and Treatment, 2019
- Body composition is associated with risk of toxicity-induced modifications of treatment in women with stage I–IIIB breast cancer receiving chemotherapyBreast Cancer Research and Treatment, 2018
- Association of Muscle and Adiposity Measured by Computed Tomography With Survival in Patients With Nonmetastatic Breast CancerJAMA Oncology, 2018
- Impact of body fat distribution on neoadjuvant chemotherapy outcomes in advanced breast cancer patientsCancer Medicine, 2015
- Body fat composition impacts the hematologic toxicities and pharmacokinetics of doxorubicin in Asian breast cancer patientsBreast Cancer Research and Treatment, 2014
- Pre-diagnosis body mass index and survival after breast cancer in the After Breast Cancer Pooling ProjectBreast Cancer Research and Treatment, 2011